Short name: Gd-DTPA mesoporphyrin, generic name: gadophrin, central moiety: Gd2+
Gadophrin is a substance under development (Bayer Schering Pharma AG) as a positive enhancing myocardium- and necrosis- targeted MRI contrast agent.

See also Metalloporphyrins and Necrosis Avid Contrast Agent.

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:

Short name: Gd-DTPA mesoporphyrin, generic name: gadophrin, central moiety: Gd2+
Gd-DTPA mesoporphyrin is a substance under development (Bayer Schering Pharma AG) as a positive enhancing myocardium- and necrosis- targeted MRI contrast agent.

See also Metalloporphyrins and Necrosis Avid Contrast Agent.

Porphyrins occur naturally in plants and animals. All porphyrin molecules feature an aromatic macrocycle ring with a central binding site. This site accommodates transition metals, which are held in place by inward-facing nitrogen atoms. Metalloporphyrins have usually a low toxicity and a potential of a selective uptake in tumors or necrosis. These properties are advantageous for a use as MRI tumor specific agents with positive enhancement. These contrast agents enhance tumors on T1 weighted sequences, which are isointense to surrounding tissues. Porphyrin-based compounds have also necrosis avid properties; they can depict the extent of myocardial infarction as defined by histopathology.
Metalloporphyrins are also used in photodynamic therapy of tumors. The compounds contain a 'lone star' metal atom at the center of the ring and are 'bigger than the average porphyrin'. They contain five N atoms in the central chelating core and this allows them to form complexes with large trivalent lanthanide metals, which have useful cancer therapy properties.

See also Classifications, Characteristics, etc., Gadophrin, MnIIITPPS4, Necrosis Avid Contrast Agent.

(NACA) Some porphyrin (e.g. Gadophrin-2) and non-porphyrin (e.g. CEIII-60) paramagnetic chelates are able to specifically accumulate in nonviable tissues and can be applied as a MRI contrast agent for acute myocardial infarction and therapeutic necrosis. This function of necrosis avid contrast agents is a unique pathological targetability. These agents can also be exploited for multipurpose applications, because NACAs also bear other common properties including early systemic distribution, albumin binding, hepatocellular uptake and renal elimination.

See also the related poll result: 'The development of contrast agents in MRI is'